| Michael Denning, | |
|
3201 Pacific Blvd Sw, Albany, OR 97321-7705 | |
| (541) 248-7073 | |
| Not Available |
| Full Name | Michael Denning |
|---|---|
| Gender | Male |
| Speciality | Massage Therapist |
| Location | 3201 Pacific Blvd Sw, Albany, Oregon |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780925107 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 201390797 (Oregon) | Secondary |
| 225700000X | Massage Therapist | 14735 (Oregon) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Michael Denning, 2908 Pine St Se, Albany, OR 97322-5620 Ph: (503) 234-9591 | Michael Denning, 3201 Pacific Blvd Sw, Albany, OR 97321-7705 Ph: (541) 248-7073 |
News Archive
EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today announced that the company will present a comprehensive analysis of its recently completed Phase 2b clinical trial of EVP-6124 in Alzheimer's disease at the Alzheimer's Association International Conference 2012 (AAIC), being held July 14-19, 2012 in Vancouver, British Columbia.
The Providence Service Corporation today announced that given the substantial free cash generated in the Company's record operating performance in the first half of 2009, as well as its expectations of additional free cash generation for the remainder of the year, the Board of Directors has authorized a total voluntary prepayment on its senior debt of $20 million.
Speaking on April 19 at the Experimental Biology 2009 meeting in New Orleans, Dr. Kristine Krajnak, a team leader in the Engineering and Control Technologies Branch of the Health Effects Laboratory Division of NIOSH in Morgantown, West Virginia, describes results from the first study to directly link the different physical responses of tissue that occur with exposure to different vibration frequencies with biological mechanisms underlying the development of vascular dysfunction.
American Medical News: "The National Committee for Quality Assurance is seeking input from the public on draft accountable care organization standards," which "were drafted by the organization's Accountable Care Organization Task Force comprising representatives from large integrated health care systems, academia and the insurance industry. … Establishing ACOs for Medicare and Medicaid beneficiaries is a key part of health system reform legislation" (11/1).
Lux Biosciences, Inc. today announced the completion of patient enrollment in its Phase 3 clinical study of Luveniq (oral voclosporin) for the treatment of non-infectious uveitis. Lux Biosciences anticipates that data from the Phase 3 study will be available early in the first quarter of 2013.
› Verified 9 days ago